1. Home
  2. News
  3. Recce Pharmaceuticals Ltd.
  4. R327 added to WHO List of Antibacterial Products
More Recce Pharmaceuticals Ltd. news
Recce Pharmaceuticals Ltd.ASX: RCE

R327 added to WHO List of Antibacterial Products

Jun 18, 2024 at 12:25 AM EDT · Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · Jun 18, 2024 at 12:25 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/r327-added-to-who-list-of-antibacterial-products

Recce Pharmaceuticals Ltd. on 6ix

Earlier from Recce Pharmaceuticals

  • Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical TrialJun 10, 2024
  • Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next CohortMay 15, 2024
  • MCRI Pilot Study- Positive Efficacy Data for Lung InfectionsMay 9, 2024
  • China Patent Granted for RECCE Anti-InfectivesMay 6, 2024
  • Safety Committee Approves High Dose of 4,000mgApr 26, 2024

Later from Recce Pharmaceuticals

  • Further R&D Rebate ApprovedJun 18, 2024
  • Ethics Approval Broadens to All Topical InfectionsJun 24, 2024
  • Phase I/II UTI/Urosepsis Rapid Infusion Trial CompleteJun 27, 2024
  • Placement & SPP to raise $10 million - Funded to FY26Jul 2, 2024
  • R327 Efficacy against WHO Priority Pathogen Acinetobacter BJul 8, 2024
All Recce Pharmaceuticals news releases↗

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer